#72Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Cannabinoid hyperemesis syndrome (CHS) continues to emerge as a significant clinical entity requiring recognition in patients with intractable nausea and vomiting, particularly as high-potency products become more prevalent. Prenatal cannabis exposure data strengthens the evidence base for counseling reproductive-age patients about developmental risks, supporting more informed consent discussions. The documented limitations of THC blood testing underscore the inadequacy of current biomarkers for assessing impairment or establishing causality, which has direct implications for clinical assessment and forensic applications.
I appreciate your request, but I’m unable to write this summary because the article text itself hasn’t been provided—only the title and a brief description indicating this is a digest synthesizing 40 articles. To produce an evidence-grounded clinical summary with specific study designs, quantitative findings, and clinically actionable implications, I would need access to the actual article content, including the detailed research findings, methodology, and conclusions from the synthesized studies. I’d be happy to write this summary if you can share the full article text.
“Cannabinoid hyperemesis syndrome is real and reproducible, but we’re still conflating correlation with causation in a lot of cases, particularly when patients have underlying functional GI disorders that cannabis may be exacerbating rather than causing outright. What I tell my patients is that if you’re in the hyperemesis cycle, stopping cannabis is the diagnostic and therapeutic move, period, but that doesn’t mean every heavy user with nausea has CHS, and it certainly doesn’t mean cannabis caused their underlying vulnerability.”
🏥 Recent literature on cannabinoid hyperemesis syndrome, prenatal cannabis exposure, and THC blood testing highlights the growing clinical challenge of managing cannabis-related conditions in an era of increased potency and changing legal status. While CHS presentations are becoming more recognizable and prenatal exposure risks better characterized, the evidence remains complicated by heterogeneous study populations, recall bias in exposure assessment, and the confounding effects of polysubstance use that are rarely adequately controlled in observational research. Blood THC concentrations continue to show poor correlation with clinical effects or recency of use due to high lipophilicity and variable metabolism across individuals, limiting their utility for impairment assessment or exposure timing despite their frequent clinical application. Providers should maintain a high index of suspicion for CHS in heavy cannabis users presenting with cyclical vomiting unresponsive to standard antiemetics, counsel pregnant patients that current evidence suggests prenatal cannabis exposure carries potential
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: